Switching from branded to generic inhaled medications: potential impact on asthma and COPD

Bibliography

• Available from: http://www.edctp.org/fileadmin/documents/ethics/Directive_200183EC_of_the _european _parliament.pdf [Accessed 1 May 2013]
   Google Scholar
• García-Arieta A, Gordon J. Bioequivalence requirements in the European Union: critical discussion. AAPS J 2012;14:738-48
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease. In: (CHMP) CfMPfHU editor. London: 2009
   Google Scholar
• US Food and Drug Administration. US FDA. Drug-development approval process. Scientific and regulatory considerations for bioequivalence (BE) of Dry Powder Inhalers (DPIs); 2011
   Google Scholar
• Daley-Yates P, Parkins D. Establishing bioequivalence for inhaled drugs; weighing the evidence. Expert Opin Drug Deliv 2011;8:1297-308
   PubMed Web of Science ®Google Scholar
• GINA. GINA report, global strategy for asthma management and prevention, December 2011 update. Available from: http://www.ginasthma.org/
   Google Scholar
• GOLD. Global strategy for diagnosis, management, and prevention of COPD (2011 update): global initiative for chronic obstructive lung disease. 2011. Available from: http://www.goldcopd.org/
   Google Scholar
• Price D, Summers M, Zanen P. Could interchangeable use of dry powder inhalers affect patients? Int J Clin Pract 2005;59(Suppl 149):3-6
   Web of Science ®Google Scholar
• Evans C, Cipolla D, Chesworth T, et al. Equivalence considerations for orally inhaled products for local action-ISAM/IPAC-RS European Workshop report. J Aerosol Med Pulm Drug Deliv 2012;25:117-39
   PubMed Web of Science ®Google Scholar
• Fuglsang A. The US and EU regulatory landscapes for locally acting generic/hybrid inhalation products intended for treatment of asthma and COPD. J Aerosol Med Pulm Drug Deliv 2012;25:243-7
   PubMed Web of Science ®Google Scholar
• Adams WP, Ahrens RC, Chen ML, et al. Demonstrating bioequivalence of locally acting orally inhaled drug products (OIPs): workshop summary report. J Aerosol Med Pulm Drug Deliv 2010;23:1-29
   PubMedGoogle Scholar
• Ousterhout M. Generic inhaled corticosteroids: Current status and what to expect next. Formulary 2011
   Google Scholar
• CBIP. Prescription en DCI. Propositions pour l'application pratique dans la pratique médicale et pharmaceutique et dans le dossier médical électronique; 2010
   Google Scholar
• Lung Alliance Network. Correct use of inhaled medication asthma and COPD. Amersfoort: 2011
   Google Scholar
• Stenson J. Report questions generic antidepressant. MASNB 2007
   Google Scholar
• Liow K, Barkley G, Pollard JR, et al. Position statement on the coverage of anticonvulsant drugs for treatment of epilepsy. Neurology 2007;68:1249-50
   PubMed Web of Science ®Google Scholar
• AACE TES ATA. Joint position statement on the use and interchangeability of thyroxine products. 2004. Available from: Thyroid.org AACE, TES and ATA [Cited 2007]
   Google Scholar
• Azouz W, Chrystyn H. Clarifying the dilemmas about inhalation techniques for dry powder inhalers: integrating science with clinical practice. Prim Care Respir J 2012;21:208-13
   PubMedGoogle Scholar
• Molimard M, Raherison C, Lignot S, et al. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med 2003;16:249-54
   PubMedGoogle Scholar
• Doyle S, Lloyd A, Williams A, et al. What happens to patients who have their asthma device switched without their consent? Prim Care Respir J 2010;19:131-9
   PubMedGoogle Scholar
• PHARMAC. New Zealand pharmaceutical schedule update effective. PHARMAC; Wellington: 2005
   Google Scholar
• Dockhorn D, Vanden Burgt J, Ekholm BP, et al. Clinical equivalence of a novel non-chlorofluorocarbon-containing salbutamol sulfate metered-dose inhaler and a conventional chlorofluorocarbon inhaler in patients with asthma. J Allergy Clin Immunol 1995;96:50-6
   PubMed Web of Science ®Google Scholar
• Gillies J, Brown J, Byrnes C, et al. PHARMAC and ventolin in New Zealand. NZ Med 2005;120:1220
   Google Scholar
• Reti S. Ventolin to Salamol – a crossover study in New Zealand. NZ Med 2006;119:1-7
   Google Scholar
• Chang C, Cooray M, Mills G, Hancox R. Is Salamol less effective than Ventolin? A randomized, blinded, crossover, study in New Zealand. NZ Med 2007;120:1267
   Google Scholar
• Thorsson L, Edsbäcker S. Lung deposition of budesonide from a pressurized metered-dose inhaler attached to a spacer. Eur Respir J 1998;12:1340-5
   PubMed Web of Science ®Google Scholar
• Thomas M, Price D, Chrystyn H, et al. Inhale corticosteroids for asthma: impact of practice level device switching on asthma control. BMC Pulm Med 2009;9:1
   PubMedGoogle Scholar
• Lavorini F, Magnan A, Dubus J, et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med 2008;102:593-604
   PubMed Web of Science ®Google Scholar
• Lavorini F, Levy M, Dekhuijzen P, Crompton G. Inhaler choice and inhalation technique: key factors for asthma control. Prim Care Respir J 2009;18:241-2
   PubMedGoogle Scholar
• Price D. Do healthcare professionals think that dry powder inhalers can be used interchangeably? Int J Clin Pract Suppl 2005;149:26-9
   PubMedGoogle Scholar
• Booker R. Do patients think that dry powder inhalers can be used interchangeably? Int J Clin Pract 2005;59(Suppl 149):30-2
   Web of Science ®Google Scholar
• Williams A, Chrystyn H. Survey of pharmacists' attitude towards interchangeable use of dry powder inhaler. Pharm World Sci 2007;29:221-7
   PubMed Web of Science ®Google Scholar
• Available from: www.longalliantie.nl/images/library/pdf/Definitief%20rapport%20Goed%20gebruik%20Inhalatiemedicatie%20astma%20en%20COPD%20december%202011%20Max.pdf
   Google Scholar